RT 100

Drug Profile

RT 100

Alternative Names: Ad5-AC6; Ad5.hAC6; Adenylate cyclase gene therapy - Renova; RT100

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Renova Therapeutics
  • Class Gene therapies
  • Mechanism of Action Adenylate cyclase expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 19 Dec 2017 RT 100 receives Fast Track designation for Heart failure [Intracoronary] in USA
  • 14 Dec 2017 Renova Therapeutics plans the phase III FLOURISH (Heart Failure with Reduced Left Ventricular Ejection Fraction: One-time Gene Transfer Using RT-100 – Intracoronary Administration of Adenovirus 5 encoding Human AC6) trial for Heart failure in USA in first quarter of 2018 (NCT03360448)
  • 04 Aug 2017 RT 100 is still in phase II development for Heart failure in USA (Renova Therapeutics, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top